134894-60-3

Upstream product

• 6854-07-5 2-hydroxy-5-nitropyridine-3-carboxylic acid 
• 134894-58-9 N-(2-hydroxy-4-methylphenyl)-2-chloro-5-nitro-3-pyridinecarboxamide 
• 135795-55-0 2-chloro-3-chlorocarbonyl-5-nitropyridine 
• 42959-38-6 3-carboxy-2-chloro-5-nitro pyridine 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 134894-59-0 9-methyl-3-nitropyrido<2,3-b><1,5>benzoxazepin-5(6H)-one 
• 74-88-4 methyl iodide 

Downstream Products

• 134894-45-4 3-amino-6,9-dimethylpyrido<2,3-b><1,5>benzoxazepin-5(6H)-one 

Relevant academic research and scientific papers

Pyrido[2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and thiones and their use on the treatment of HIV infection

Disclosed are pyrido[2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and -thiones. These are useful in the prevention or treatment of AIDS.

Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones

Dibenzoxazepin-11(10H)-ones (III), pyridobenzoxazepin-6(5H)-ones (IV), and pyridobenzoxazepin-5(6H)-ones (V) were found to inhibit human immunodeficiency virus type 1 reverse transcriptase with IC50 values as 19 nM.A-ring substitution has a profound effect on activity, with appropriate substituents at the positions ortho and para to the lactam nitrogen providing dramatically enhanced potency.Substitution in the C-ring is generally neutral or detrimental to activity.Although a C-ring amino substituent at the position meta to the lactam carbonyl is generally beneficial to activity, it has essentially no effect when the A-ring is optimally substituted.Like the dipyridodiazepinone nevirapine, compounds III-V are specific for HIV-1 RT, exhibiting no inhibitory activity against HIV-2 RT or other virial reverse transcriptase enzymes.